Inherited Genes Shape Tumor Evolution After DNA Damage
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- University of Cambridge researchers co-led a Nature study providing the first direct evidence that inherited genetic background steers how cancer begins and evolves after DNA damage, using four mouse strains with varying susceptibility to liver cancer to mimic human population-level genetic diversity.
- The research team administered the same dose of the liver carcinogen diethylnitrosamine (DEN) — found in tobacco smoke and some processed foods — to all mice at 15 days old under controlled conditions, then sequenced the genomes of nearly 600 resulting tumors and compared them against untreated mice.
- Tumors in all four mouse strains almost always activated the same MAPK cancer-promoting signaling pathway, yet the specific driver mutations that emerged depended on each strain's inherited genetics, indicating that the biological endpoint is conserved but the route to it is not.
- Certain genetic backgrounds showed a striking tendency toward whole-genome duplication, in which the complete set of chromosomes is copied — a distinct molecular event the researchers linked to inherited variation rather than random mutation.
- Senior author Professor Duncan Odom, now at DKFZ (German Cancer Research Centre), said: 'Cancer does not arise entirely by chance. Although tumors often reach the same biological endpoint, the path to that endpoint is determined by an individual's genetic background.'
- First author Dr. Sarah Aitken, now an Assistant Professor at Yale School of Medicine, said future cancer prevention and screening strategies must account for inherited genetics and population diversity, and that responses to DNA-damaging cancer drugs are likely to vary by genetic background.
- The work was co-led by Professor Duncan Odom, Dr. Sarah Aitken, and Professor Martin Taylor across the University of Cambridge, the University of Edinburgh, and institutions in Europe and the US, and was funded by Cancer Research UK, the Medical Research Council, the European Research Council, and Wellcome.
Why it matters: This is the first controlled evidence that inherited genes — not just environment or acquired mutations — independently steer tumor evolution, meaning two patients with identical exposures could follow different molecular routes to the same cancer subtype. That complicates one-size-fits-all treatment and strengthens the case for genetically tailored screening and drug selection in precision oncology.
